| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Otilonium bromide (SP-63; Octylonium bromide; SP63; trade name Spasmomen among others) is a potent anti-muscarinic agent and a CCB (calcium channel blocker) used to relieve spasmodic pain of the gut, in particular in irritable bowel syndrome. Otilonium bromide is a quaternary ammonium compound whose spasmolytic action, selective on the distal gastrointestinal tract, is mainly due to its direct myolytic properties. This drug modifies Ca2+ fluxes from extracellular and intracellular pools in the intestinal smooth muscle and is poorly absorbed, thus it exerts its action locally, without any considerable systemic effect.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Arch Int Pharmacodyn Ther.1983 Aug;264(2):305-23;Aliment Pharmacol Ther.1998 Oct;12(10):1003-10.
|
| Molecular Formula |
C29H43BRN2O4
|
|
|---|---|---|
| Molecular Weight |
563.57
|
|
| Exact Mass |
562.24
|
|
| CAS # |
26095-59-0
|
|
| Related CAS # |
Otilonium-d4 bromide
|
|
| PubChem CID |
72092
|
|
| Appearance |
White to off-white solid powder
|
|
| Melting Point |
130-133ºC
|
|
| LogP |
3.398
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
17
|
|
| Heavy Atom Count |
36
|
|
| Complexity |
600
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
VWZPIJGXYWHBOW-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H
|
|
| Chemical Name |
diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7744 mL | 8.8720 mL | 17.7440 mL | |
| 5 mM | 0.3549 mL | 1.7744 mL | 3.5488 mL | |
| 10 mM | 0.1774 mL | 0.8872 mL | 1.7744 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02576340 | Completed | Drug: otilonium bromide | Gastroscopy | Konya Meram State Hospital | January 2013 | Phase 4 |
| NCT01629212 | Unknown † | Drug: Tiropramide HCl 100mg Drug: Octylonium bromide 20mg |
Irritable Bowel Syndrome | Daewoong Pharmaceutical Co. LTD. | December 2011 | Phase 4 |
| NCT04270487 | Completed | Other: IBS Diet Drug: Otilonium Bromide |
Irritable Bowel Syndrome | Universitaire Ziekenhuizen KU Leuven | July 26, 2018 | Phase 4 |
| NCT05461833 | Completed | Biological: Fecal transplantation Drug: OTILONII BROMIDUM Dietary Supplement: multi-strain probiotic |
Irritable Bowel Syndrome | Bogomolets National Medical University |
September 1, 2020 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA